Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1273553 | 1.00 | KDM1A (0.66) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL31278806 | 0.88 | KDM1A (0.55) | KDM1AMEN1KMT2AMAOBSIGMAR1 | |
| SCHEMBL7441079 | 0.88 | KDM1A (0.55) | KDM1AMEN1KMT2AMAOBSIGMAR1 | |
| SCHEMBL18088758 | 0.88 | KDM1A (0.55) | KDM1AMEN1KMT2AMAOBSIGMAR1 | |
| SCHEMBL2464182 | 0.88 | KDM1A (0.55) | KDM1AMEN1KMT2AMAOBSIGMAR1 | |
| Hydrochloric Acid SCHEMBL26916642 | 0.86 | KDM1A (0.53) | KDM1AMEN1KMT2AMAOBSIGMAR1 | |
| Propane SCHEMBL27768603 | 0.82 | KDM1A (0.50) | KDM1AMEN1KMT2AMAOBSIGMAR1 | |
| SCHEMBL17988045 | 0.79 | KDM1A (1.00) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL578812 | 0.79 | KDM1A (0.59) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL1101137 | 0.79 | KDM1A (0.59) | KDM1AMEN1KMT2AAKR1B1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-11878979-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2024-01-23 | — | — | US | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-11572357-B2 | Quinoline derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2023-02-07 | — | — | US | disclosed |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-08-02 | — | — | US | disclosed |
| CN-109311902-B | Substituted imidazo [1,2-b ] pyridazines, imidazo [1,5-b ] pyridazines, related compounds, and uses thereof | BIAL研发投资股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2022-06-16 | — | — | US | disclosed |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20140288023-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-25 | — | — | US | disclosed |
| CN-102245562-B | Process for the synthesis of amino-methyltetralin derivatives | HOFFMANN LA ROCHE | 2014-08-13 | — | — | CN | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| CN-102245562-A | Process for the synthesis of amino-methyltetralin derivatives | HOFFMANN LA ROCHE | 2011-11-16 | — | — | CN | disclosed |
| US-7737167-B2 | 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | KDM1A 846/4885MEN1 3196/4885KMT2A 771/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | KDM1A 491/4885MEN1 3638/4885KMT2A 1108/4885 |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | GRIN2C, COMT, NLN | KDM1A 3995/4885MEN1 2159/4885KMT2A 2037/4885 |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | KDM1A 889/4885MEN1 2957/4885KMT2A 612/4885 |
| US-11878979-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | KDM1A 410/4885MEN1 1026/4885KMT2A 303/4885 |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, GALC | KDM1A 410/4885MEN1 1026/4885KMT2A 303/4885 |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, QTRT2 | KDM1A 905/4885MEN1 654/4885KMT2A 1122/4885 |
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | SERPINA2, FABP1, TTR | KDM1A 4169/4885MEN1 3457/4885KMT2A 4403/4885 |
| US-20140288023-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | KDM1A 4358/4885MEN1 4082/4885KMT2A 4639/4885 |
| US-11572357-B2 | Quinoline derivatives | RECQL, NQO2, QTRT2 | KDM1A 914/4885MEN1 683/4885KMT2A 1142/4885 |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | H1-5, H1-10, H1-0 | KDM1A 417/4885MEN1 543/4885KMT2A 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.